Identification of paramyosin T cell epitopes associated with human resistance to Schistosoma mansoni reinfection

Clinical and Experimental Immunology

Volumn 142, Issue 3, 2005, Pages 539-547

  Fonseca, C T ^a   Cunha Neto, E ^b   Goldberg, A C ^b   Kalil, J ^b   De Jesus, A R ^c   Carvalho, E M ^c   Correa Oliveira, R ^d   Hammer, J ^e   Sidney, J ^f   Sette, A ^f   Oliveira, Sergio Costa ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e HOFFMANN LA ROCHE INC   (United States)

^f LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Paramyosin; Schistosoma mansoni; Synthetic peptides; T cells; Vaccine

Indexed keywords

HLA DR ANTIGEN; MUSCLE PROTEIN; MYOPROTEIN; PARAMYOSIN; SCHISTOSOMA VACCINE; UNCLASSIFIED DRUG;

ALGORITHM; ALLELE; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN; IN VITRO STUDY; INFECTION RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REINFECTION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 28344456594     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02941.x     Document Type: Article

References (35)

1. Chitsulo L, Loverde P, Engels D. Schistosomiasis. Nat Rev Micro-biol 2004; 2:12-13.
2. Boros DL. Immunopathology of Schistosoma mansoni infection. Clin Microbiol Rev 1989; 2:250-69.
3. Coles GC, Bruce JI, Kinoti GK, Mutahi WT, Dias EP, Katz N. Drug resistance in schistosomiasis. Trans R Soc Trop Med Hyg 1986; 80:347-51.
4. Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxaminiquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 1994; 51:83-8.
5. Bergquist NR. Schistosomiasis vaccine development: approaches and prospects. Mem Inst Oswaldo Cruz 1995; 90:221-7.
6. Capron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 2005; 21:143-9.
7. McManus DP, Bartley PB. A vaccine against Asian schistosomiasis. Parasitol Int 2004; 53:163-73.
8. Pearce EJ, James SL, Hieny S, Lanar DE, Sher A. Induction of pro-tective immunity against Schistosoma mansoni by vaccination with schistosome Paramyosin (Sm97), a nonsurface parasite antigen. Proc Natl Acad Sci USA 1988; 85:5678-82.
9. Lanar DE, Pearce EJ, James SL, Sher A. Identification of Paramyo-sin as schistosome antigen recognized by intradermally vaccinated mice. Science 1986; 234:593-6.
10. Flanigan TP, King CH, Lett RR, Nanduri J, Mahmoud AA. Induc-tion of resistance to Schistosoma mansoni infection in mice by puri-fied parasite Paramyosin. J Clin Invest 1989; 83:1010-14.
11. Ribeiro de Jesus A, Araujo I, Bacellar O et al. Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect Immun 2000; 68:2797-803.
12. Correa-Oliveira R, Pearce EJ, Oliveira GC et al. The human immune response to denned immunogens of Schistosoma mansoni: elevated antibody levels to Paramyosin in stool-negative individu-als from two endemic areas in Brazil. Trans R Soc Trop Med Hyg 1989; 83:798-804.
13. Al-Sherbiny M, Osman A, Barakat R, El Morshedy H, Bergquist R, Olds R. In vitro cellular and humoral responses to Schisto-soma mansoni vaccine candidate antigens. Acta Trop 2003; 88:117-30.
14. Colley DG, Cook JA, Freeman GL Jr, Bartholomew RK, Jordan P. Immune responses during human Schistosomiasis mansoni. I. In vitro lymphocyte blastogenic responses to heterogeneous antigenic preparations from schistosome eggs, worms and cercariae. Int Arch Allergy Appl Immunol 1977; 53:420-33.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of pro-tein-dye binding. Anal Biochem 1976; 72:248-54.
16. Sturniolo T, Bono E, Ding J et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17:555-61.
17. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alterna-tive to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39:225-35.
18. Sette A, Sidney J, del Guercio MF et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol 1994; 31:813-22.
19. Southwood S, Sidney J, Kondo A et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363-73.
20. Buus S, Sette A, Colon SM, Miles C, Grey HM. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 1987; 235:1353-8.
21. Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, Grey HM. The measurement of MHC/peptide interactions by gel infil-tration. Curr Protocols Immunol 1998; 18:1-19.
22. Iwai LK, Yoshida M, Sidney J et al. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasileinses frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Mol Med 2003; 9:1-12.
23. Panigada M, Sturniolo T, Besozzi G et al. Identification of a pro-miscuous T-cell epitope in Mycobacterium tuberculosis Mce pro-teins. Infect Immun 2002; 70:79-85.
24. Fonseca CT, Cunha-Neto E, Kalil J et al Identification of immun-odominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells. Mem Inst Oswaldo Cruz 2004; 99(Suppl. 1):63-6.
25. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol 2002; 2:499-511.
26. Correa-Oliveira R, Malaquias LC, Falcao PL et al. Cytokines as determinants of resistance and pathology in human Schistosoma mansoni infection. Braz J Med Biol Res 1998; 31:171-7.
27. Gazarian KG, Gazarian TG, Solis CF., Hernández R, Shoemarker CB, Laclet JP. Epitope mapping on N-terminal region of Taenia solium paramyosin. Immunol Lett 2000; 72:191-5.
28. Meloen RH, Langeveld JP, Schaaper WM, Slootstra JW. Synthetic peptide vaccines: unexpected fulfillment of discarded hope? Bio-logicals 2001; 29:233-6.
29. Agiro L, Henri S, Dessein H, Kouriba B, Dessein AJ, Bourgois A. Induction of protection against S. mansoni with a MAP containing epitopes of Sm37-GAPDH and Sm10-DLC. Effect of coadsorbtion with GM-CSF on alum. Vaccine 2000; 18:2033-8.
30. Tallima H, Montash M, Veprek P, Velek J, Jezek J, El Ridi R. Dif-ferences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase. Vaccine 2003; 21:3290-300.
31. Tarrab-Hazdai R, Schechtman D, Arnon R. Synthesis and charac-terization of a protective peptide-based vaccine against Schistosoma mansoni. Infect Immun 1998; 66:4526-30.
32. Nara T, Tanabe K, Mahakunkijcharoen Y, Osada Y, Matsumoto N, Kita K, Kojima S. The B-cell epitope of Paramyosin recognized by a protective monoclonal IgE antibody to Schistosoma japomicum. Vaccine 1997; 15:79-84.
33. Vilar MM, Barrientos F, Almeida M et al. An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis. Vaccine 2003; 22:137-44.
34. + T cell epitopes of Taenia solium Paramyosin. Parasite Immunol 2003; 25:513-16.
35. Vázquez-Talavera J, Solis CF, Medina-Escutia E et al Human T and B cell epitope mapping of Taenia solium Paramyosin. Parasite Immunol 2001; 23:575-9.